Armata Pharmaceuticals, Inc. — Director's Dealing 2023

Feb 7, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Armata Pharmaceuticals, Inc. (ARMP)
CIK: 0000921114
Period of Report: 2022-07-01

Reporting Person: Butler Erin (Vice President,Finance & Admin)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$14.28	2027-09-17	Common Stock (714)		Direct
Stock Option (Right to Buy)	$3.15	2029-05-22	Common Stock (15000)		Direct
Stock Option (Right to Buy)	$5.14	2031-03-24	Common Stock (30000)		Direct
Stock Option (Right to Buy)	$5.11	2032-04-12	Common Stock (50000)		Direct

Footnotes

F1: Reflects the grant of stock options to purchase shares of common stock of the Issuer under the Issuer's 2016 Equity Incentive Plan (the "2016 EIP"). All 714 stock options are fully vested and exercisable.

F2: Reflects the grant of stock options to purchase shares of common stock of the Issuer under the 2016 EIP. 11,250 of the stock options are fully vested and exercisable. 3,750 of the stock options will vest on May 22, 2023.

F3: Reflects the grant of stock options to purchase shares of common stock of the Issuer under the 2016 EIP. 7,500 of the stock options are fully vested and exercisable. 7,500 of the stock options will vest on March 25, 2023, 7,500 of the stock options will vest on March 25, 2024, and 7,500 of the stock options will vest on March 25, 2025.

F4: Reflects the grant of stock options to purchase shares of common stock of the Issuer under the 2016 EIP. None of the stock options have fully vested and become exercisable. 12,500 of the stock options will vest on April 13, 2023, 12,500 of the stock options will vest on April 13, 2024, 12,500 of the stock options will vest on April 13, 2025, and 12,500 of the stock options will vest on April 13, 2026.